Suba Krishnan

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Medicine, Oncology, Urology +12

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al. · International Journal of Cancer · 2020 · 498 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al. · Journal of Thoracic Oncology · 2019 · 438 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi et al. · Clinical Cancer Research · 2016 · 412 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Margaret K. Callahan, Harriet M. Kluger, Michael A. Postow et al. · Journal of Clinical Oncology · 2017 · 189 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17